ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX): Second Quarter 2007 Financial Results Include: * Revenues were $95.7 million, an increase of 32% over second quarter of 2006 * Diluted earnings per share, before a non-cash expense of $0.10 per share related to the Company’s redemption of its 1.75% Contingent Convertible Senior Subordinated Notes (see note (a) to the financials accompanying this release), a non-GAAP measure, were $0.39, an increase of 44% over second quarter of 2006
